The 2023 OASIS 1 trial evaluated the efficacy and safety of oral semaglutide 50 mg daily in 667 adults with overweight or obesity without type 2 diabetes. Over 68 weeks, participants receiving semaglutide experienced a mean weight loss of 15.1%, compared to 2.4% with placebo. Notably, 85% of the semaglutide
